Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Metabolic Dysfunction-Associated Fatty Liver Disease: Which Option is the Better Choice?
Authors:
- 25 February 2025
- journal article
- review article
- Published by IMR Press in British Journal of Hospital Medicine
- Vol. 86 (2) , 1-5
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease and is linked to metabolic syndrome components such as insulin resistance and obesity. In 2020, the term “metabolic dysfunction-associated fatty liver disease (MAFLD)” was introduced, incorporating metabolic risk factors and including patients with other liver conditions. However, concerns about the term “fatty” led to the proposal of the term “metabolic dysfunction-associated steatotic liver disease (MASLD)”, which refined diagnostic criteria but excluded patients with significant alcohol consumption or liver comorbidities. Although MASLD improves NAFLD in some respects, its exclusion of comorbid conditions may hinder comprehensive care for metabolic dysregulation. A proposed solution is “combinatorial MASLD”, which would better address patients with liver comorbidities. Further studies are necessary to determine the most appropriate nomenclature for clinical practice.Keywords
This publication has 8 references indexed in Scilit:
- Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunction-associated steatotic liver diseaseHepatoma Research, 2024
- Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?Hepatology International, 2023
- Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALDJournal of Hepatology, 2023
- Letter to the Editor: Statement of steatotic liver disease—A great leap toward the global standardizationHepatology, 2023
- A multisociety Delphi consensus statement on new fatty liver disease nomenclatureHepatology, 2023
- Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United StatesJournal of Hepatology, 2021
- MAFLD identifies patients with significant hepatic fibrosis better than NAFLDLiver International, 2020
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJournal of Hepatology, 2020